Varenicline and antiretroviral therapy in patients with HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 5, 2009, Pages 656-

  Tornero, Carlos ^a   Mafé, Carmen ^a  

^a Section of Hematology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; RITONAVIR; STAVUDINE; TIPRANAVIR; VARENICLINE; ANTIRETROVIRUS AGENT; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

CARDIOVASCULAR RISK; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; OXIMETRY; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VOMITING; CARDIOVASCULAR DISEASE; FEMALE; MALE;

ANTI-RETROVIRAL AGENTS; BENZAZEPINES; CARDIOVASCULAR DISEASES; FEMALE; HIV INFECTIONS; HUMANS; MALE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION;

EID: 73349098245     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ba1beb     Document Type: Letter

References (5)

1. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
2. Tornero C, Santamaria A, Gil E, et al. Indices de riesgo cardiovascular en pacientes con infecciòn por el virus de la inmunodeficiencia humana en tratamiento antirretroviral efectivo. Med Clin (Barc). 2008;130:797.
3. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Eng J Med. 2008;359: 2018-2024.
4. Eisenberg MJ, Kristian MPH, Filion MSc, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179: 135-144.
5. Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adult special populations. Ann Intern Med. 2006;145:845-856.